tiprankstipranks
Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A (BR:CLOV34)
:CLOV34
Brazil Market
CLOV34
Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A
RESEARCH TOOLSreports

Compare Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A (CLOV34) vs. Competitors

Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Compare
Top Analysts' Price Target
Smart Score
Follow
Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A
R$13.11B
-90,090.09
42.12%
Enovis Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh
R$5.69B
-935.42
-48.81%
Ultragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
R$7.22B
-2,351.20
-58.38%
Sarepta Therapeutics, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
R$11.06B
-6,566.53
9.75%
Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333333 Sh
R$5.73B
-179,817.04
-25.12%
DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
R$10.68B
-3,748.60
-38.12%

Performance Comparison

Ticker
Company Name
Price
Change
% Change
BR:CLOV34
Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A
22.00
5.24
31.26%
BR:E2NO34
Enovis Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh
24.39
-18.44
-43.05%
BR:R2AR34
Ultragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
7.30
-8.42
-53.56%
BR:S1RP34
Sarepta Therapeutics, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
5.29
0.69
15.00%
BR:T2DH34
Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333333 Sh
31.45
-8.75
-21.77%
BR:XRAY34
DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
56.00
-32.91
-37.02%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts